SPI1<sup>+</sup>CD68<sup>+</sup> macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies
The present study showed that SPI1<sup>+</sup>CD68<sup>+</sup> TAMs are a promising biomarker for predicting prognosis, antiangiogenic drug sensitivity, and combination target of immunotherapy in patients with GC.
Authors
- Guofei Deng
- Rishun Su
- Mingyu Huo (ORCID: https://orcid.org/0000-0002-2817-8391)
- Songcheng Yin (ORCID: https://orcid.org/0000-0002-6156-8797)
- Xuezeng Sun
- Liang Gu (ORCID: https://orcid.org/0000-0002-0308-636X)
- Hong Yu (ORCID: https://orcid.org/0000-0001-5740-2543)
- Changhua Zhang (ORCID: https://orcid.org/0000-0003-0678-4574)
- Zhenzhen Zhao (ORCID: https://orcid.org/0000-0002-3182-9511)
- Zhangsen Huang (ORCID: https://orcid.org/0000-0003-1546-0977)
- Yulong He (ORCID: https://orcid.org/0000-0001-8930-8404)
- Pengliang Wang (ORCID: https://orcid.org/0000-0001-6166-7560)
- Zizhen Wu (ORCID: https://orcid.org/0000-0003-4018-1750)
Institutions
- Sun Yat-sen University (CN)
- Peking University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Peking University People's Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/jitc-2024-009983
- Citations
- 15
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.61
Funders
- National Natural Science Foundation of China
- Sanming Project of Medicine in Shenzhen
- Basic and Applied Basic Research Foundation of Guangdong Province